Flortaucipir F 18

Drug Profile

Flortaucipir F 18

Alternative Names: 18F-AV-1451; [18F]-T-807; [3H]AV 1451; [F-18]T807; F-18-AV-1451; Fluorine 18 AV 1451; T807

Latest Information Update: 08 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Siemens Medical Solutions
  • Developer Avid Radiopharmaceuticals; Northwestern University; University of Pennsylvania
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Alzheimer's disease
  • Phase II Brain injuries; Cognition disorders; Dementia; Depressive disorders; Neurodegenerative disorders; Progressive supranuclear palsy
  • Phase I Aphasia

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Neurodegenerative-disorders(Diagnosis) in USA (IV, Injection)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Progressive-supranuclear-palsy(Diagnosis) in USA (IV, Injection)
  • 13 Jun 2018 Avid Radiopharmaceuticals completes a phase trial in Alzheimer's disease (Diagnosis, In adults, In the elderly) in USA and Australia (NCT02516046)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top